Skip to main content
JEONJINBIO CO., LTD. logo

JEONJINBIO CO., LTD. — Investor Relations & Filings

Ticker · 110020 ISIN · KR7110020005 KO Manufacturing
Open in API
Filings indexed 370 across all filing types
Latest filing 2024-06-13 M&A Activity
Country KR South Korea
Listing KO 110020

About JEONJINBIO CO., LTD.

http://jjbious.com/01

JEONJINBIO CO., LTD. is a biotechnology company specializing in the research, development, and production of products for pest control and the mitigation of damage from nuisance animals. The company's core offerings consist of natural bio-pesticides and repellents formulated from natural materials as alternatives to conventional chemical products. Its product line includes specialized solutions for repelling birds, boars, and other animals. The company emphasizes innovation and safety, supported by its dedicated research and development center and various product certifications, including USA EPA approval for its bird repellent.

Recent filings

Filing Released Lang Actions
최대주주변경을수반하는주식양수도계약해제ㆍ취소등
M&A Activity Classification · 1% confidence The document is a regulatory filing from a Korean company (Jeonjin BioPharm) announcing the cancellation of a stock purchase agreement that would have resulted in a change of the largest shareholder. This type of disclosure regarding M&A-related agreements, specifically the termination of a share transfer contract, falls under the category of M&A Activity (TAR) as it pertains to the control and ownership structure of the company.
2024-06-13 Korean
[기재정정]기타경영사항(자율공시) (제8회 무기명식 이권부 무보증 사모 전환사채 취득 후 재매각의 건-철회)
Capital/Financing Update Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Correction Report' (정정신고) regarding a previous 'Other Management Matter' (기타 경영사항). It details the cancellation of a previously announced resale of convertible bonds due to non-payment of the balance. This falls under the category of financing and capital structure updates, as it concerns the management of convertible bonds (debt/equity instruments). Since it is a specific update on a financing transaction rather than a general regulatory announcement, 'CAP' (Capital/Financing Update) is the most accurate classification.
2024-06-13 Korean
[기재정정]기타경영사항(자율공시) (제9회 무기명식 이권부 무보증 사모 전환사채 취득후 재매각의 건-철회)
Capital/Financing Update Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Correction Report' (정정신고) regarding a previous 'Other Management Disclosure' (기타 경영사항). It details the cancellation of a previously announced resale of convertible bonds due to non-payment of the balance. Since this is a specific regulatory announcement regarding corporate financing and capital structure changes (convertible bonds), it falls under the 'Capital/Financing Update' category.
2024-06-13 Korean
[기재정정]임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official filing from Jeonjin BioPharm regarding the results of an Extraordinary General Meeting (EGM). It specifically details the outcome of the meeting, which was to adjourn (continue) the meeting to a later date, and provides the updated schedule. This falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports the formal status and procedural outcome of a shareholder meeting.
2024-06-10 Korean
전환청구권행사
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding the exercise of conversion rights (전환청구권행사) for convertible bonds. This type of filing details changes in capital structure, specifically the conversion of debt into equity, which directly impacts the number of shares outstanding. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'SHA' category.
2024-06-07 Korean
[기재정정]기타경영사항(자율공시) (제8회 무기명식 이권부 무보증 사모 전환사채 취득 후 재매각의 건)
Capital/Financing Update Classification · 1% confidence The document is a regulatory filing from a Korean company (Jeonjin BioPharm) regarding a correction to a previous disclosure about the resale of convertible bonds. It details specific changes to the completion date of the bond resale. Since this is a regulatory announcement regarding capital structure and financing activities (specifically convertible bonds), and it does not fit into the specific categories like 'Share Issue' or 'M&A', it is best classified as a general regulatory filing.
2024-06-07 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.